Get Premium to unlock powerful stock data

Fate Therapeutics to Present at Upcoming Investor Conferences

Author's Avatar
Marketwired
Mar 08, 2021
Article's Main Image

SAN DIEGO, March 08, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) ( FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, announced today that the Company will present at the following upcoming investor conferences:

  • Barclays Global Healthcare Conference on Thursday, March 11, 2021 from 11:30-11:55AM ET
  • Oppenheimer Virtual 31st Annual Healthcare Conference on Wednesday, March 17, 2021 from 1:10-1:40PM ET

A live webcast, if recorded, of each presentation can be accessed under "Events & Presentations" in the Investors section of the Company's website at www.fatetherapeutics.com. The archived webcast will be available on the Company's website shortly after the event.

About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Company’s immuno-regulatory product candidates include ProTmune™, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease. Fate Therapeutics is headquartered in San Diego, CA.

Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
[email protected]

ti?nf=ODE4NTQ5MSM0MDUxMjY3IzIwMDQyMDE=
b396c7dd-aad8-4447-b6c1-ffc4b020f37f
Not a Premium Member of GuruFocus? Sign up for a free 7-day trial here.
Rating:
0 / 5 (0 votes)

Please Login to leave a comment